Entera Bio Ltd (ENTX) Stock Analysis

Entera Bio Ltd (ENTX) is a publicly traded company in the HEALTHCARE sector. It trades at $1.25, carries a market capitalization of $62.52M. This page summarizes the public market data, fundamentals, and frequently asked questions for ENTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Entera Bio Ltd currently has a Bullish sentiment score of 0.29.

About Entera Bio Ltd

Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, that is pioneering innovative oral delivery systems for large molecule therapeutics. Focusing on substantial unmet medical needs, the company leverages its proprietary platform to enhance patient compliance and broaden therapeutic options. Entera Bio's promising pipeline features advanced therapies designed to improve the efficacy and accessibility of treatments, thus positioning the compa...

GNG Research Analysis

GNG Research scores Entera Bio Ltd (ENTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ENTX.

Frequently Asked Questions

Does ENTX pay dividends?

Entera Bio Ltd (ENTX) does not currently pay a regular dividend.

What is ENTX's market cap?

Entera Bio Ltd (ENTX) has a market capitalization of $62.52M with a current stock price of $1.25.